Medacta Group SA

Medacta Group SA revenues up +19.5% at constant currency1 exceeding the milestone of 500Mln € in FY 2023 - Seite 2

Innovation is at the core of our growth strategy and allows us to differentiate our product offering and service portfolio. In October we launched GMK SpheriKA, the world's first knee implant optimized for Kinematic Alignment (KA), to improve patient satisfaction compared to more traditional techniques. Our continued commitment to medical education, through in-person scientific events and our M.O.R.E. Institute programs for surgeons, has been foundational to excellent performance throughout the entire 2023. 

Revenue by geography and product line

Group performance was very positive in every market thanks to a confirmed strong growth in EMEA, North America, and APAC. In every region the growth was sustained by organically expanding our salesforce and customer base together with some new product introduction.

Revenue in EMEA grew c.c. 22.6%, to Euro 242.4 million, a significant performance driven by all the Business lines.

Revenue in North America increased 15.7% c.c. to Euro 154.0 million, a strong performance boosted by some patient backlog recovery in the first half of the year.

Revenue in Asia Pacific grew by 19.4% c.c. to Euro 104.2 million.

Revenue in Latin America was Euro 10.2 million with an increase of 11.9% c.c.

Below we report the FY 2023 sales break-down by geographic area:

(Million Euro)	FY 2023	FY 2022	Reported Growth	Constant Currency Growth
EMEA*	242.4	196.7	23.3%	22.6%
North America	154.0	136.8	12.6%	15.7%
Asia Pacific	104.2	94.4	10.4%	19.4%
Latin America*	10.2	9.3	9.0%	11.9%
TOTAL	510.8	437.1	16.8%	19.5%